#United States #New York #Pomerantz LLP #investors #I-Mab

Investigation Overview

The legal firm Pomerantz LLP has initiated an investigation concerning claims made on behalf of investors associated with I-Mab, a publicly traded biopharmaceutical company listed on NASDAQ under the ticker symbol IMAB. Investors are encouraged to reach out to Danielle Peyton via the firm's contact details provided in their announcement. This inquiry is centered around potential securities fraud and other unlawful practices that may have been perpetrated by I-Mab and its executive team.

Recent Developments

On October 16, 2025, I-Mab revealed a significant shift in its business strategy, introducing a new business model aimed at accelerating high-value assets through partnerships. The company's redefined focus involves a 'hub-and-spoke' structure, establishing specialized subsidiary companies to enhance agility and operational effectiveness. Additionally, an ambitious plan was shared regarding the pursuit of an Initial Public Offering (IPO) in Hong Kong, which is expected to coincide with a dual listing on both the NASDAQ and the Hong Kong Stock Exchange (HKEX). Furthermore, the company plans to undergo a rebranding to NovaBridge Biosciences to reflect this new phase of growth.

Stock Market Reaction

Following the disclosure of these strategic changes, I-Mab's American Depositary Receipt (ADR) experienced a notable drop, declining by $0.79 or 12.04%, leading to a closing price of $5.77 per ADR the subsequent trading day. Investors often react swiftly to such announcements, primarily if the revised business model raises concerns over prior operational transparency or profitability. The nature and consequences of these transitions might lead to wider implications for stakeholders, sparking questions about investor trust and company governance moving forward.

The Role of Pomerantz LLP

Recognized as a leader in corporate and securities litigation, Pomerantz LLP has a storied history of championing investors in class action suits with its roots dating back over 85 years. The firm’s founder, Abraham L. Pomerantz, is widely regarded as a pioneer in the area of securities class actions. The firm's success is marked by numerous multimillion-dollar recoveries for class members affected by corporate fraud and mismanagement. Their ongoing commitment remains focused on upholding shareholder rights and pursuing justice for affected investors.

Call to Action

Investors holding positions in I-Mab are encouraged to come forward and seek further information regarding the class action. The potential allegations against the company underscore the need for vigilance among shareholders who deserve clarity and accountability from their investments. As developments unfold, the investigation's outcome might pave the way for further legal actions depending on the findings related to the company's business practices.

For additional details or to participate in the class action, interested investors should reach out to Danielle Peyton at Pomerantz LLP directly. Keeping abreast of ongoing news and legal developments will be essential for stakeholders navigating these potential changes in I-Mab’s trajectory.